We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FTC has stopped investigating whether Allergan or its licensing partner, Syntex International (now Roche Palo Alto), took anticompetitive actions to delay generic competition to Acular (ketorolac tromethamine ophthalmic solution 0.5%), an anti-inflammatory indicated for use after cataract surgery.
A generic subsidiary of Novartis has filed an antitrust claim against GlaxoSmithKline (GSK) over patents related to Augmentin, GSK revealed Feb. 11 in its 2003 earnings report.
Israeli generic firm Dexxon has been sued by GlaxoSmithKline (GSK) in Israel to stop marketing a version of GSK’s indigestion drug Zantac (ranitidine HCl) under the similar trademark Zanidex.
Legislation pending in the House intended to fix a patent law problem, which has had a chilling effect on collaborative research between industry and universities, could produce some unintended problems of its own, according to the Biotechnology Industry Organization (BIO).
The FTC has notified Allergan that it has stopped investigating whether the company or its licensing partner, Syntex International (now Roche Palo Alto), took anticompetitive actions to delay generic competition to Acular (ketorolac tromethamine ophthalmic solution 0.5%), an anti-inflammatory indicated for use after cataract surgery.
New guidelines issued by the Health Industry Group Purchasing Association (HIGPA), which represents 175 healthcare purchasing and supply chain organizations, could help strengthen drugmakers’anticounterfeiting efforts.
A 10-year-old lawsuit against Wyeth being considered for possible review by the U.S. Supreme Court could set a legal precedent for patent law in the United States.
GlaxoSmithKline (GSK) has filed a lawsuit in Israel seeking a court order to stop generic drugmaker Dexxon from marketing a version of GSK's indigestion drug Zantac (ranitidine HCl) under the similar trademark Zanidex.